Antimicrobial Susceptibility Testing Market Size, Growth Rate and Segmentation Outlook to 2034

CDI's estimate for the antimicrobial susceptibility testing market puts it at USD 9.68 billion by 2034, compounding at 8.5% a year. That places it above the rate CDI models for the durable medical equipment market, at 6.12%, and above the mammography market's 7.56%, while sitting just under the 9.31% forecast for the dermatology devices market and the 9.56% forecast for prefilled syringes. Across the five markets CDI covers with a disclosed rate, antimicrobial susceptibility testing runs closer to the faster end than the slower one, without leading the group outright.

The report does not disclose a base-year dollar figure for this market, so the number to hold onto is the forecast endpoint: USD 9.68 billion by 2034, at 8.5% a year to get there.

The report has not modeled a single principal driver for this market the way it has for some of CDI's other device markets, so the growth case here rests on what the segmentation itself shows about where the market has spread. It is scoped across nine separate axes: product type, test method, organism type, application, specimen type, end user, testing site, distribution channel, and testing standard. That is a wide scope for a diagnostics category, and it reflects how far antimicrobial susceptibility testing has moved past a single method.

The test-method axis alone runs from disk diffusion, the oldest manual technique in the category, through broth microdilution, gradient diffusion, automated broth microdilution systems, genotypic and molecular AST, and MALDI-TOF MS-based AST. Having automated and molecular methods sit in the same segmentation as a manual plate-based technique says something about the state of the category: laboratories are not migrating off older methods so much as running a wider set of them side by side, each suited to a different specimen, organism, or turnaround requirement.

The application axis carries the same signal. Clinical diagnostics sits alongside drug discovery and antimicrobial development, epidemiological and AMR surveillance, food, water and environmental testing, and veterinary and animal health testing. A market segmented this way draws demand from outside the hospital lab as well as inside it, touching drug development pipelines and surveillance programs directly. The same breadth shows up in the dermatology devices market, where CDI's segmentation separates diagnostic devices from treatment devices within a single clinical category, and in the mammography market, where digital, 3D, analog and film-screen systems all sit inside one product axis instead of one dominant format.

The report has not modeled a downside case or a named restraint for this market, so the friction points worth noting are the ones visible in the segmentation itself rather than a forecast range. The testing-standard axis splits the market between CLSI-based testing and EUCAST-based testing, alongside other national and regional standards. Two breakpoint systems operating in parallel is a structural feature of this category, not an incidental one, and a laboratory or instrument maker built around one standard does not automatically serve markets that have standardized on the other.

The testing-site axis carries a related split: centralized or reference laboratory testing sits alongside point-of-care and near-patient testing, with decentralized on-site hospital lab testing tracked as a third category of its own. A market divided this way across method, standard, and setting has no single product that answers the whole opportunity. A supplier's addressable share depends on how many of these categories its platform actually reaches.

The report does not disclose a regional or segment-level revenue split for this market, so the where of it is best read through the range of end users and settings its own segmentation covers, rather than a numeric distribution. On the end-user axis, hospital and clinical laboratories sit alongside independent reference and commercial laboratories, academic and research institutes, pharmaceutical and biotechnology companies, and public health and government agencies. That is a wider buyer base than a market confined to hospital procurement, and demand for this category does not move only with hospital capital budgets as a result.

The specimen-type axis narrows the clinical side of that demand further: blood and blood culture, urine, respiratory specimens, wound, tissue and pus, stool, and cerebrospinal and other sterile body fluids are each broken out on their own. That level of detail matches the kind of clinical-diagnostics depth CDI models in the durable medical equipment market, where monitoring and therapeutic devices are split out from the broader equipment category, and in the mammography market, where screening and diagnostic use are tracked as separate applications rather than folded into one.

Readers who want a market with a disclosed regional and segment split alongside a comparable growth rate can find one in the dermatology devices market, at 9.31% to 2034, where CDI's data breaks out both the leading region and the leading product line.